Literature DB >> 11683371

Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse.

B Brocks1, P Garin-Chesa, E Behrle, J E Park, W J Rettig, K Pfizenmaier, D Moosmayer.   

Abstract

BACKGROUND: Fibroblast activation protein (FAP) is a type II membrane protein expressed on tumor stroma fibroblasts in more than 90% of all carcinomas. FAP serves as a diagnostic marker and is potential therapeutic target for treatment of a wide variety of FAP+ carcinomas. Murine tumor stroma models and FAP-specific antibodies are required to investigate the functional role of FAP in tumor biology and its usefulness for drug targeting. We here describe the development of antibodies with crossreactivity for human (hFAP) and murine FAP (mFAP), which share 89% amino acid identity.
MATERIAL AND METHODS: An FAP-/- mouse was sequentially immunized with recombinant murine and human FAP-CD8 fusion proteins. Immunoglobulin cDNA derived from hyperimmune spleen cells was used for the construction of a combinatorial single chain Fv (scFv) library. Phage display selection of FAP-specific scFv was performed on immobilized hFAP followed by selection on cells expressing murine FAP.
RESULTS: High-affinity, species-crossreactive, FAP-specific scFv were isolated upon sequential phage display selection. A bivalent derivative (minibody M036) constructed thereof was applied for immunohistochemical analyses and allowed detection of FAP expression on stroma cells of different human carcinomas as well as on murine host stroma in a tumor xenograft model.
CONCLUSIONS: MB M036, derived from phage display selected species crossreactive scFv, is suitable for tumor stroma targeting and will be a valuable tool in the analyses of the functional role of FAP in tumor biology as well as in the evaluation of the suitability of FAP for drug targeting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683371      PMCID: PMC1950057     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  13 in total

1.  Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format.

Authors:  Sina Fellermeier; Nadine Beha; Jan-Erik Meyer; Sarah Ring; Stefan Bader; Roland E Kontermann; Dafne Müller
Journal:  Oncoimmunology       Date:  2016-09-27       Impact factor: 8.110

2.  An automated immunoassay for early specificity profiling of antibodies.

Authors:  Katrin Frese; Meike Eisenmann; Ralf Ostendorp; Bodo Brocks; Stefan Pabst
Journal:  MAbs       Date:  2013-02-14       Impact factor: 5.857

3.  Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen.

Authors:  Mohammadreza Movahedin; Teresa M Brooks; Nitin T Supekar; Naveen Gokanapudi; Geert-Jan Boons; Cory L Brooks
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

Review 4.  Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.

Authors:  Alain E Andrea; Andrada Chiron; Sarah Mallah; Stéphanie Bessoles; Guillaume Sarrabayrouse; Salima Hacein-Bey-Abina
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

5.  FAP-Targeted Photodynamic Therapy Mediated by Ferritin Nanoparticles Elicits an Immune Response against Cancer Cells and Cancer Associated Fibroblasts.

Authors:  Shiyi Zhou; Zipeng Zhen; Amy V Paschall; Lijun Xue; Xueyuan Yang; Anne-Gaelle Bebin-Blackwell; Zhengwei Cao; Weizhong Zhang; Mengzhe Wang; Yong Teng; Gang Zhou; Zibo Li; Fikri Y Avci; Wei Tang; Jin Xie
Journal:  Adv Funct Mater       Date:  2020-11-09       Impact factor: 19.924

6.  A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice.

Authors:  Jinxu Fang; Liang Xiao; Kye-Il Joo; Yarong Liu; Chupei Zhang; Shuanglong Liu; Peter S Conti; Zibo Li; Pin Wang
Journal:  Int J Cancer       Date:  2015-09-14       Impact factor: 7.396

7.  Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.

Authors:  Sunitha Kakarla; Kevin K H Chow; Melinda Mata; Donald R Shaffer; Xiao-Tong Song; Meng-Fen Wu; Hao Liu; Lisa L Wang; David R Rowley; Klaus Pfizenmaier; Stephen Gottschalk
Journal:  Mol Ther       Date:  2013-06-04       Impact factor: 11.454

8.  A fast and effective determination of the biodistribution and subcellular localization of fluorescent immunoliposomes in freshly excised animal organs.

Authors:  Felista L Tansi; Ronny Rüger; Ansgar M Kollmeier; Claudia Böhm; Roland E Kontermann; Ulf K Teichgraeber; Alfred Fahr; Ingrid Hilger
Journal:  BMC Biotechnol       Date:  2017-01-18       Impact factor: 2.563

9.  Targeting the Tumor Microenvironment with Fluorescence-Activatable Bispecific Endoglin/Fibroblast Activation Protein Targeting Liposomes.

Authors:  Felista L Tansi; Ronny Rüger; Ansgar M Kollmeier; Markus Rabenhold; Frank Steiniger; Roland E Kontermann; Ulf K Teichgräber; Alfred Fahr; Ingrid Hilger
Journal:  Pharmaceutics       Date:  2020-04-17       Impact factor: 6.321

10.  Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy.

Authors:  Ting Huang; Huiqiang Wang; Nanhai G Chen; Alexa Frentzen; Boris Minev; Aladar A Szalay
Journal:  Mol Ther Oncolytics       Date:  2015-03-18       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.